High-risk myeloma is a moving target. Myeloma plasma cells always learn to fight back. The key to treating myeloma is to fight multiple targets, understand the biology, and find out why myeloma is becoming more aggressive. In this episode, ACCRU podcast host Dr. Kristen Ciombor interviews Dr. Shebli Atrash, who specializes in hematology and oncology at the Levine Cancer Institute in Charlotte, N.C. He is also a Community Member of the ACCRU Board of Directors. Dr. Atrash discusses what drew him to hematology oncology and shares what needs to be improved in high-risk myeloma research. His current myeloma study with ACCRU will enroll approximately 42 patients across 7 centers. Dr. Atrash also shares his advice for junior investigators getting started in their field of research.
Create your
podcast in
minutes
It is Free